胰岛类器官治疗1型糖尿病的临床研究进展  

Recent advance in clinical researches of islet organoids for treating type 1 diabetes mellitus

作　　者：张博雅[1] 蔡湘衡 王树森[1] Zhang Boya;Cai Xiangheng;Wang Shusen(Department of Cell Transplantation,First Central Municipal Hospital,Tianjin 300384,China)

机构地区：[1]天津市第一中心医院细胞移植科,天津300384

出　　处：《中华器官移植杂志》2024年第9期641-644,F0003,共5页Chinese Journal of Organ Transplantation

基　　金：国家重点研发计划(2020YFA0803704);天津市卫生健康科技项目(TJWJ2021QN015)。

摘　　要：1型糖尿病(type 1 diabetes mellitus,T1DM)是一种自身免疫性疾病,患者需长期使用胰岛素治疗。目前,胰岛移植已经成为治疗T1DM的常规方法,可以减缓糖尿病性微血管病变的发展,降低糖尿病的死亡率,但现阶段胰岛移植的临床推广严重受限于供体胰腺短缺。近年来,胰岛类器官治疗T1DM研究取得了重要进展,不仅促进了胰岛再生领域的发展,也有望成为治疗T1DM的理想方法。本文就胰岛类器官的细胞来源、胰岛类器官培养的优化方式以及临床应用的研究进展进行概述,为胰岛类器官治疗T1DM临床转化提供参考。Type 1 diabetes mellitus(T1DM)is a multifactorial autoimmune disease and T1DM patients require insulin therapy.Capable of delaying the process of diabetic microangiopathy and lowering diabetes-related mortality,islet transplantation has become an ideal treatment of T1DM.However,islet transplantation is severely limited by an acute shortage of donor pancreas.In recent years,islet regeneration is gaining popularity.This review focused upon an overview of cell sources of islet organoids,optimization methods for islet organoids culture and research advances in clinical applications,providing references for clinical transformation of islet organoids for T1DM.

关 键 词：1型糖尿病 胰岛移植 类器官 干细胞 

分 类 号：R587.1[医药卫生—内分泌]